Grandfield & Dodd’s Intellia Therapeutics NTLA Stock Holding History

Grandfield & Dodd’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$841K	Buy	49,680 +1,250	+3%	+$17.5K	0.04%	124
2026 Q1	$621K	Buy	48,430 +210	+0.4%	+$2.67K	0.04%	131
2025 Q4	$433K	Sell	48,220 -2,570	-5%	-$35.4K	0.02%	152
2025 Q3	$877K	Buy	50,790 +2,085	+4%	+$25.7K	0.05%	114
2025 Q2	$457K	Buy	48,705 +60	+0.1%	+$493	0.03%	141
2025 Q1	$346K	Buy	48,645 +17,550	+56%	+$177K	0.02%	159
2024 Q4	$363K	Buy	31,095 +18,085	+139%	+$282K	0.02%	162
2024 Q3	$267K	Buy	+13,010	New	+$300K	0.02%	189

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Grandfield & Dodd's NTLA Position: Q2 2026 in Review

Grandfield & Dodd increased its Intellia Therapeutics (NTLA) stake by 2.6% in Q2 2026, buying an estimated $17.5K and bringing the position to 49,680 shares worth $841K. The position accounts for 0.04% of the portfolio, ranked #124.

Grandfield & Dodd first reported a position in NTLA in Q3 2024 and has held it in 8 quarters since. The position peaked at $877K in Q3 2025. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Grandfield & Dodd held 49,680 shares of Intellia Therapeutics worth $841K as of Q2 2026.
Grandfield & Dodd bought 1,250 Intellia Therapeutics shares in Q2 2026, an estimated $17.5K.
Intellia Therapeutics made up 0.04% of Grandfield & Dodd's portfolio in Q2 2026, its #124 holding.
Grandfield & Dodd first reported a position in Intellia Therapeutics in Q3 2024 and has held it in 8 quarters since.
Grandfield & Dodd's Intellia Therapeutics position peaked at $877K in Q3 2025.
328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Grandfield & Dodd's 13F filing for Q2 2026, filed 7 Aug 2026.